A study of novel anti-cancer agents in patients with metastatic triple negative breast cancer

Trial Identifier: D933LC00001
Sponsor:AstraZeneca
NCTID:NCT03742102
Start Date:December 2018
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

CountryLocation
GB Cambridge, GB, CB2 0QQ
GB London, GB, W1T 7HA
GB London, GB, EC1M 6BQ
GB Manchester, GB, M20 4BX
GB Oxford, GB, OX3 7LE
KR Seoul, KR, 05505
KR Seoul, KR, 06351
KR Seoul, KR, 03080
US, PA Philadelphia, PA, US, 19124
US, MO Saint Louis, MO, US, 63110
US, AZ Tucson, AZ, US, 85715
TW Kaohsiung, TW, 80756
TW Taichung, TW, 40447
TW Tainan City, TW, 70403
TW Taipei, TW, 10002
TW Taoyuan, TW, 333
PL Bialystok, PL, 15-027
PL Gdańsk, PL, 80-214
PL Gliwice, PL, 44-101
PL Kraków, PL, 30-688
PL Łódź, PL, 90-302
PL Lublin, PL, 20-090
PL Opole, PL, 45-060
PL Poznań, PL, 61-848
PL Rzeszów, PL, 35-021
PL Warszawa, PL, 02-781
PL Warszawa, PL, 04-141
PL Warszawa, PL, 02-507
CA, QC Greenfield Park, QC, CA, J4V 2H1
CA, QC Montreal, QC, CA, H4A 3J1
CA, ON London, ON, CA, N6A 5W9
CA, ON Toronto, ON, CA, M4N 3M5
CA, BC Kelowna, BC, CA, V1Y 5L3
US, MA Boston, MA, US, 02114
US, MA Boston, MA, US, 02215
US, VA Fairfax, VA, US, 22031
US, VA Williamsburg, VA, US, 23188
US, TX Dallas, TX, US, 75246
US, TX Houston, TX, US, 77030
US, TX San Antonio, TX, US, 78240
US, CA West Hollywood, CA, US, 90048